Skip to main content
. Author manuscript; available in PMC: 2017 Mar 15.
Published in final edited form as: Clin Cancer Res. 2015 Nov 6;22(6):1520–1530. doi: 10.1158/1078-0432.CCR-15-1259

Figure 3. Analyses in PDX.

Figure 3

(A) PDX development relative to start of ADT and chemotherapy. Numbers indicate PDX line. The MDA-PCa 163 PDX line was derived from the prostate tumor of patient #80 on NCT00514540 in the non-castrate setting (pink shaded box). Blue shade indicates SCPC morphology. Purple shade indicates castration-resistant prostate tumor without SCPC morphology. (B) Western blot analyses of markers of interest and Tp53 mutations (shown in red) in PDX. Abbreviations: PDX, patient-tumor derived xenograft; ADT, androgen deprivation therapy; WT, wild-type.